Skip to main content

Table 1 Patient demographics

From: Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma

  Characteristic

Overall

 

n

%

Number

24

 

Age

  

Range

35-70

Median

60

Sex

  

Male

17

71%

Female

7

39%

Stage

  

II

4

16.5%

III

16

67%

IV

4

16.5%

Karnofsky performance status

90%

7

29%

100%

16

67%

Unknown

1

4%

Prior therapy

  

None

17

71%

Temozolomide alone

1

4.1%

Radiation alone

2

8.3%

RSA ablation

1

4.1%

Interferon

1

4.1%

Temozolomide +

1

4.1%

Radiation

Temozolomide +

1

4.1%

Isolated limb infusion